Vimarsana
Biggest News Aggregation in the World

Page 3 - Gary Jacob News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gary Jacob. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gary Jacob Today - Breaking & Trending Today

January transfer window: our writers' Premier League predictions - Vimarsana News

January transfer window: our writers' Premier League predictions

From Serhou Guirassy to Ivan Toney and Dominic Solanke, we assess which players are most likely to be signed or sold this month in our team-by-team guide

OKYO Pharma on track as last patient enrolled in trial to treat dry eye disease completes final protocol visit - Vimarsana News

OKYO Pharma on track as last patient enrolled in trial to treat dry eye disease completes final protocol visit

OKYO Pharma Ltd (NASDAQ:OKYO) told investors that it is on track to release top-line results from its phase 2 clinical trial of OK-101 to treat dry eye...

OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal Pain - Vimarsana News

OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal Pain

OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, told investors it has filed an Investigational New Drug (IND) application with the US Food...

OKYO Pharma phase II dry eye trial making encouraging progress - Vimarsana News

OKYO Pharma phase II dry eye trial making encouraging progress

OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, has reported encouraging safety data for its ongoing phase II clinical trial of OK-101, a...

Related Topics:
Gary JacobOkyo Pharma Ltd
OKYO Pharma completes enrollment in Phase 2 trial to treat dry eye disease - Vimarsana News

OKYO Pharma completes enrollment in Phase 2 trial to treat dry eye disease

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has completed full enrollment of patients in the randomized portion of the Phase 2 multi-center,...